{"id":"gtx-104","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Colitis"},{"rate":"null","effect":"Hypothyroidism"}]},"_chembl":{"chemblId":"CHEMBL3545017","moleculeType":"Small molecule","molecularWeight":"341.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GTX-104 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thus enhancing the immune response against cancer cells.","oneSentence":"GTX-104 is a small molecule that targets the PD-1/PD-L1 pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:35.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT05995405","phase":"PHASE3","title":"Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grace Therapeutics Inc.","startDate":"2023-10-20","conditions":"Aneurysmal Subarachnoid Hemorrhage (aSAH)","enrollment":100},{"nctId":"NCT05418348","phase":"PHASE1","title":"Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects","status":"COMPLETED","sponsor":"Grace Therapeutics Inc.","startDate":"2021-08-26","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GTX-104","genericName":"GTX-104","companyName":"Grace Therapeutics Inc.","companyId":"grace-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GTX-104 is a small molecule that targets the PD-1/PD-L1 pathway. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}